Physician profile

Vulihn Ta

Obstetrics & Gynecology · Lemoore, CA

NPI 1114965308

$1,553.21

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$521.84

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Hologic Sales and Service, LLC $556.93 2020-2023 Omni Hysteroscope, Acessa Provu System
Intuitive Surgical, INC. $310.16 2019-2022
Abbvie INC. $210.11 2019-2023 Orilissa, Lo Loestrin Fe
Organon LLC $208.04 2024
Astrazeneca Pharmaceuticals LP $124.52 2021
Bayer Healthcare Pharmaceuticals INC. $75.64 2019-2024
Minerva Surgical, INC $36.19 2019
Coopersurgical, INC. $31.62 2023 Vaginal Speculum - Snowman/ Pederson Blade

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Vulihn Ta

$1,553.21

in general payments reported 2019-2025

Years
2019-2024
Top company
Hologic Sales and Service, LLC

https://glasscript.com/doctor/565677/vulihn-ta

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.